Introduction A new era of treatment for adults with treatment-resistant depression (TRD),
which involves psychedelic substances, is dawning. Emerging evidence indicates that …

Introduction: It is a basic principle of the “psychedelic” treatment model that the quality of the
acute experience mediates long-term improvements in mental health. In the present paper …

Background Patients diagnosed with major depressive disorder (MDD) who fail to respond
to two or more antidepressants are often considered to have treatment-resistant depression …

ABSTRACT This Special Issue of Neuropharmacology on psychedelics provides a timely
and comprehensive update on progress following the previous Neuropharmacology Special …

Major depressive disorder (MDD) is a serious psychiatric disorder that is characterized by
feelings of sadness and/or loss of interest in pleasurable activities. MDD can affect all age …

BackgroundRandomised controlled trials (RCTs) of psilocybin have reported large
antidepressant effects in adults with major depressive disorder and treatment-resistant …

Psilocybin is the most researched classic psychedelic for Treatment-Resistant Depression
(TRD). While optimizing set and setting are considered essential for efficacy and safety …

Despite the popular support for psychedelics as aids for depression, academics and the
public frequently overestimate the efficacy of available medications and psychotherapies …

There is a serious need for novel therapies that treat individuals with depression, including
major depressive disorder (MDD) and treatment-resistant depression (TRD). An emerging …

Background and aims Given the enormous global burden of depressive illness, there is an
urgent need to develop novel and more effective treatments for major depressive disorder …